NASDAQ:PMCB PharmaCyte Biotech (PMCB) Stock Price, News & Analysis $1.18 +0.04 (+3.04%) As of 04/17/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About PharmaCyte Biotech Stock (NASDAQ:PMCB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PharmaCyte Biotech alerts:Sign Up Key Stats Today's Range$1.03▼$1.2050-Day Range$1.13▼$1.8152-Week Range$1.03▼$2.42Volume13,357 shsAverage Volume21,539 shsMarket Capitalization$8.13 millionP/E Ratio2.24Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.Read More… PharmaCyte Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScorePMCB MarketRank™: PharmaCyte Biotech scored higher than 48% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for PharmaCyte Biotech. Earnings and Valuation1.9 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of PharmaCyte Biotech is 2.24, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.41.Price to Earnings Ratio vs. SectorThe P/E ratio of PharmaCyte Biotech is 2.24, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.94.Price to Book Value per Share RatioPharmaCyte Biotech has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.33% of the float of PharmaCyte Biotech has been sold short.Short Interest Ratio / Days to CoverPharmaCyte Biotech has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PharmaCyte Biotech has recently decreased by 24.63%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPharmaCyte Biotech does not currently pay a dividend.Dividend GrowthPharmaCyte Biotech does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.33% of the float of PharmaCyte Biotech has been sold short.Short Interest Ratio / Days to CoverPharmaCyte Biotech has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PharmaCyte Biotech has recently decreased by 24.63%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News SentimentN/A News SentimentPharmaCyte Biotech has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for PharmaCyte Biotech this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added PharmaCyte Biotech to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PharmaCyte Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders10.20% of the stock of PharmaCyte Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 34.24% of the stock of PharmaCyte Biotech is held by institutions.Read more about PharmaCyte Biotech's insider trading history. Receive PMCB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address PMCB Stock News HeadlinesMyMD Pharmaceuticals Secures Strategic InvestmentsMay 21, 2024 | businesswire.comPharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory DiseaseMay 21, 2024 | businesswire.comHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we believe are in immediate danger.April 20, 2025 | Behind the Markets (Ad)PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024December 18, 2023 | msn.comCompanies Like PharmaCyte Biotech (NASDAQ:PMCB) Are In A Position To Invest In GrowthDecember 15, 2023 | finance.yahoo.comPharmaCyte Biotech Inc PMCBDecember 5, 2023 | morningstar.comPharmaCyte Biotech Invests In Femasys - Quick FactsNovember 15, 2023 | markets.businessinsider.comFemasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte BiotechNovember 15, 2023 | finance.yahoo.comSee More Headlines PMCB Stock Analysis - Frequently Asked Questions How have PMCB shares performed this year? PharmaCyte Biotech's stock was trading at $1.57 at the beginning of 2025. Since then, PMCB shares have decreased by 24.5% and is now trading at $1.1850. View the best growth stocks for 2025 here. How were PharmaCyte Biotech's earnings last quarter? PharmaCyte Biotech, Inc. (NASDAQ:PMCB) announced its earnings results on Monday, March, 17th. The company reported ($0.10) EPS for the quarter. How do I buy shares of PharmaCyte Biotech? Shares of PMCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PharmaCyte Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that PharmaCyte Biotech investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), ASML (ASML), General Electric (GE), Oracle (ORCL) and Nokia Oyj (NOK). Company Calendar Last Earnings3/17/2025Today4/20/2025Fiscal Year End4/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PMCB CIK1157075 Webpharmacyte.com Phone917-595-2850Fax917-595-2851Employees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.74 Trailing P/E Ratio2.24 Forward P/E RatioN/A P/E GrowthN/ANet Income$330,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity0.76% Return on Assets0.45% Debt Debt-to-Equity RatioN/A Current Ratio4.47 Quick Ratio4.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.27 per share Price / Book0.36Miscellaneous Outstanding Shares6,864,000Free Float6,896,000Market Cap$8.13 million OptionableOptionable Beta-0.53 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:PMCB) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCyte Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmaCyte Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.